X4 Pharmaceuticals, Inc.
XFOR
$0.2033
-$0.0067-3.19%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.43M | 560.00K | 563.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.43M | 560.00K | 563.00K | -- | -- |
| Cost of Revenue | 302.00K | 227.00K | 268.00K | -- | -- |
| Gross Profit | 1.13M | 333.00K | 295.00K | -- | -- |
| SG&A Expenses | 15.15M | 15.66M | 13.28M | 17.44M | 9.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.15M | 35.06M | 34.46M | 37.29M | 25.20M |
| Operating Income | -35.72M | -34.50M | -33.90M | -37.29M | -25.20M |
| Income Before Tax | -39.56M | -36.68M | 90.85M | -51.75M | -19.10M |
| Income Tax Expenses | 258.00K | 15.00K | 18.00K | 19.00K | 33.00K |
| Earnings from Continuing Operations | -39.82M | -36.70M | 90.83M | -51.77M | -19.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.82M | -36.70M | 90.83M | -51.77M | -19.13M |
| EBIT | -35.72M | -34.50M | -33.90M | -37.29M | -25.20M |
| EBITDA | -35.44M | -34.23M | -33.70M | -37.23M | -25.14M |
| EPS Basic | -0.20 | -0.18 | 0.45 | -0.26 | -0.10 |
| Normalized Basic EPS | -0.12 | -0.11 | -0.04 | -0.16 | -0.06 |
| EPS Diluted | -0.20 | -0.18 | 0.45 | -0.26 | -0.10 |
| Normalized Diluted EPS | -0.12 | -0.11 | -0.04 | -0.16 | -0.06 |
| Average Basic Shares Outstanding | 202.93M | 200.87M | 200.44M | 199.99M | 198.77M |
| Average Diluted Shares Outstanding | 202.93M | 200.87M | 200.80M | 199.99M | 198.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
